Mirna Therapeutics, a top biotechnological firm that develops and commercializes microRNA (miRNA) therapeutics, appointed Dr. Clay B. Siegall as an external director and advisor of its Board of Directors on January 30, 2013. Mirna’s CEO and head, Dr. Paul Lammers, applauded Dr. Clay Siegall for agreeing to join the firm’s notable group of directors. He noted that Clay Siegall’s long-term pharmaceutical professional expertise and achievement in developing a prosperous oncology company would be instrumental for both Mirna team and its board.
About Mirna Therapeutics
Mirna Therapeutics has a dynamic portfolio of miRNA products developed by its scientists. The firm’s IP portfolio comprises of more than 300 miRNAs with applications in the specialty of oncology. Oncology-directed miRNAs consist of dominant suppressors of tumors in cancer including miR-34 and let-7 that have proven their ability to block the growth of tumor in a variety of pre-clinical animal studies. The Austin, Texas-based Mirna Therapeutics has received significant financing from both the State of Texas and private investors.
About Dr. Clay Siegall
Since co-founding Seattle Genetics in 1998, Dr. Clay has focused on building a dynamic line of antibody-based medications to solve unaddressed medical needs of people with cancer. In 2011, the company introduced its first certified and commercial product known as ADCETRIS. The firm has established strong connections with top pharmaceutical and biotechnology corporations in oncology. Dr. Clay Siegall has directed several capital-raising activities on behalf of Settle Genetics. These activities have generated over $675 million through IPO back in 2001, public, and private financing.
Academics and career
Dr. Clay is a talented and experienced scientist holding an undergrad in Zoology and a Ph.D. in Genetics. He is a proud alumnus of two prestigious universities: George Washington University and the University of Maryland. He started his research career at the National Cancer Institute back in 1988. He was also a senior researcher at the National Institutes of Health. He became part of Bristol-Myers Squibb Pharmaceutical Research Institute in 1991 and relinquished his influential position in 1997. He developed a passion for cancer research and decided to establish his firm (Seattle Genetics) in 1998 with a goal of leveraging antibody-based therapies to fight cancer.